Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ASTRO 2017: Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin in Patients with High-Risk, Early-Stage Endometrial Cancer

Results of phase III GOG study
25 Oct 2017
Gynaecological Malignancies

Results of the Gynecology Oncology Group (GOG) phase III study presented in a plenary session of 2017 ASTRO Annual Meeting (24-27 September, San Diego, USA) did not demonstrate a superiority of vaginal cuff brachytherapy and chemotherapy (VCB/C) to pelvic external beam radiation therapy (PXRT) in women with high-risk, early endometrial cancer. Acute and late toxicity and pelvic and para-aortic nodal failure were more frequent in the VCB/C arm. Both arms appeared to be well tolerated with high completion rates.

The primary study objective was to determine if VCB/C could increase recurrence-free survival (RFS) compared to PXRT. Secondary objectives included comparisons of overall survival (OS), patterns of failure, and frequency/severity of adverse events between the treatment arms.

All patients in the study were required to undergo hysterectomy. Eligible patients had stage I endometrioid histology with GOG 99-based high intermediate risk criteria (based on age, tumour grade, depth of invasion, and presence of lymphovascular space invasion), stage II, or stage I-II serous or clear cell tumours. Central pathology review was performed.

Patients assigned to PXRT were treated with standard 4-field or Intensity-Modulated Radiation Therapy (IMRT) techniques to a mean dose of 45 Gy over 5 weeks. Additional VCB was optional for patients with serous/clear cell tumours or stage II disease. Patients assigned to VCB/C received HDR or LDR brachytherapy followed by paclitaxel 175 mg/m2 plus carboplatin AUC 6 for a total of 3 cycles.

A total of 601 patients were accrued; PXRT was assigned to 301 (18 did not receive study treatment) and VCB/C to 300 (9 did not receive study treatment).

The median age was 63 years, 74% had stage I disease, and 89% underwent lymphadenectomy. Histology included 71% with endometrioid type, 15% serous, and 5% clear cell. Nearly all patients completed the prescribed therapy. 

In the PXRT arm, IMRT was used in 36%, and vaginal cuff brachytherapy boost was added in approximately 35%.

Acute toxicity was more common and more severe with VCB/C. Grade 3 or higher adverse events were reported in 32 patients on the PXRT arm versus 187 patients on the VCB/C arm. Grade 3 or higher late effects were seen in 37 and 35 patients on the PXRT and VCB/C arms, respectively.

With a median follow-up of 53 months, the 36 month RFS was 82% for both PXRT and VCB/C.

The 36-month OS was 91% versus 88% for PXRT and VCB/C, respectively. 

No significant differences were noted between the two arms in terms of vaginal or distant failure. However, pelvic or para-aortic nodal recurrences were significantly more common in the VCB/C arm (25 vs 12), largely driven by the difference in pelvic nodal failure (20 vs 6 patients). There was no statistically significant treatment effect heterogeneity with respect to RFS among clinical-pathologic variables evaluated.

The GOG investigators concluded that PXRT remains an effective, well-tolerated, and acceptable adjuvant treatment in patients with high-risk, early-stage endometrial carcinoma.

Last update: 25 Oct 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.